Arrhythmia Research Technology, Inc. (AMEX: HRT) and its subsidiary Micron Products, Inc. announced that it has entered into a multi-year supply agreement with Blue Belt Technologies, Inc. (Blue Belt) to produce orthopedic implant components used in its STRIDE” Unicondylar Knee system.Arrhythmia Research Technology, Inc. (NYSEMKT:HRT) stock opened at $5.49 in last session, and closed at $6.39, while the day range of HRT stock is $5.28-$6.41. The stock showed a positive weekly performance of 37.42%.
Manhattan Diagnostic Radiology (MDR), a wholly owned subsidiary of RadNet Inc. (NASDAQ:RDNT) announces that 3D mammography, the latest innovation in breast cancer screening, is now available at its 66th Street location. MDR is the first free-standing, full-service radiology provider in Manhattan to offer this 3D technology. Also known as breast tomosynthesis, this newest software makes 2D images from a 3D scan – an upgrade only recently approved for use by the FDA. 3D Mammography will eventually allow for faster scan times and reduced radiation exposure. RadNet Inc. (NASDAQ:RDNT) stock opened at $2.84, in last session and closed at $2.89, by gained 2.48%. The 52 week range was $1.50-$3.35. Company’s market capitalization is $115.86 million.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) was the subject of a surge in the market after registering a narrower loss for its fourth quarter. Immediately after the announcement the company’s shares surged by a high of 10.8%. Rigel Pharmaceuticals saw its fourth quarter net loss clock in at 19 cents per share against Zacks consensus estimates of 24 cents. This was a massive improvement considering the company registered a net loss of 30 cents for the same quarter a year ago. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) stock gained 5.09% and finished the last session at $4.75. The EPS of the stock remained -1.02. Company’s market capitalization is $415.74 million.
Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company. The Company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Xencor Inc (NASDAQ:XNCR) stock opened the session at $12.80, and closed the session at $13.05.The 52 week range of the XNCR stock remained $5.75-$13.23 and the day range was $12.60-$13.23.